Verteporfin has been in short supply globally since late 2020 due to capacity constraints at
the manufacturing site and has been restricted for use solely in ocular cancer centers in the
UK.
There is currently a limited quantity of stock available above what is required for the
treatment of ocular cancer and we have worked with the DHSC medicine supply team to
make this excess stock available for treatment of central serous retinopathy (CSR).
You can find details of how this stock will be distributed in the NHS National Patient Safety
Alert and read our guidance on which patients should be prioritised for treatment with this
limited stock.
If you have any queries regarding this shortage please contact Jonathan Baker, Quality
Improvement Manager: [email protected]